SCL Science Inc. (KOSDAQ: 246960)

Market Cap	69.63B
Revenue (ttm)	3.77B
Net Income (ttm)	-3.13B
Shares Out	7.28M
EPS (ttm)	-439.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	21,382
Average Volume	28,850
Open	9,640.00
Previous Close	9,680.00
Day's Range	9,590.00 - 10,000.00
52-Week Range	7,600.00 - 11,850.00
Beta	0.77
RSI	65.98
Earnings Date	Mar 21, 2025

About SCL Science

SCL Science Inc. produces medical hemostatic agents using biomimetic technology. Its products includes BiMM (Bio-inspired Medical Materials) that reacts immediately with blood; Endoseal which is used for the specialized indication of gastrointestinal bleeding; InnoSeal, a hemostatic agent that is used in various surgical fields such as cardiology, radiology, and neurosurgery; Jelly Seal, a hemostasis and sealing products; STOP, a non-bleeding intravascular injection; Film that prevents leakage at intestinal and vascular anastomosis sites; and I...

• Industry: Orthopedic, Prosthetic, and Surgical Appliances and Supplies
• Founded: 2010
• Employees: 49
• Stock Exchange: KOSDAQ
• Ticker Symbol: 246960

Financial Performance

In 2023, SCL Science's revenue was 1.32 billion, an increase of 257.54% compared to the previous year's 369.78 million. Losses were -5.03 billion, -15.83% less than in 2022.